Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kalvista Pharmaceuticals, Inc. (KALV) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kalvista Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1348911.
Total stock buying since 2015: $84,861,482.
Total stock sales since 2015: $87,358,399.
Total stock option exercises since 2015: $2,195,865.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 361,212 | $3,322,932 | 135,028 | $1,885,940 | 152,041 | $0 |
| 2024 | 732,000 | $9,646,480 | 424,144 | $5,659,753 | 476,424 | $0 |
| 2023 | 519,017 | $6,465,649 | 180,807 | $1,783,409 | 302,535 | $131,310 |
| 2022 | 0 | $0 | 14,898 | $197,333 | 71,848 | $440,499 |
| 2021 | 0 | $0 | 308,186 | $8,337,681 | 141,186 | $1,219,726 |
| 2020 | 115,686 | $1,995,814 | 84,358 | $1,507,852 | 358 | $2,412 |
| 2019 | 127,647 | $2,163,687 | 1,420,419 | $37,319,673 | 37,493 | $63,676 |
| 2018 | 1,117,648 | $19,000,016 | 31,288 | $625,999 | 0 | $0 |
| 2017 | 2,265,065 | $19,316,904 | 2,901,930 | $30,003,759 | 0 | $0 |
| 2016 | 0 | $0 | 0 | $0 | 42,429 | $332,642 |
| 2015 | 4,590,000 | $22,950,000 | 10,000 | $37,000 | 10,000 | $5,600 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-05-18 | Feener Edward P. (Chief Scientific Officer) | Sale | 1,786 | 10.14 | 18,117 |
| 2023-05-18 | Crockett Thomas Andrew (CEO) | Sale | 5,627 | 10.14 | 57,080 |
| 2023-05-18 | Palleiko Benjamin L (President, CFO, CBO & Sec'y) | Sale | 4,037 | 10.14 | 40,951 |
| 2023-05-17 | Audhya Paul K. (Chief Medical Officer) | Option Ex | 6,447 | .00 | 0 |
| 2023-05-17 | Yea Christopher (Chief Development Officer) | Option Ex | 4,205 | .00 | 0 |
| 2023-05-17 | Feener Edward P. (Chief Scientific Officer) | Option Ex | 4,205 | .00 | 0 |
| 2023-05-17 | Crockett Thomas Andrew (CEO) | Option Ex | 12,750 | .00 | 0 |
| 2023-05-17 | Palleiko Benjamin L (President, CFO, CBO & Sec'y) | Option Ex | 9,364 | .00 | 0 |
| 2023-02-17 | Audhya Paul K. (Chief Medical Officer) | Sale | 3,412 | 7.66 | 26,135 |
| 2023-02-17 | Audhya Paul K. (Chief Medical Officer) | Option Ex | 6,446 | .00 | 0 |
| 2023-02-17 | Yea Christopher (Chief Development Officer) | Sale | 2,727 | 7.66 | 20,888 |
| 2023-02-17 | Yea Christopher (Chief Development Officer) | Option Ex | 4,204 | .00 | 0 |
| 2023-02-17 | Feener Edward P. (Chief Scientific Officer) | Sale | 2,228 | 7.66 | 17,066 |
| 2023-02-17 | Feener Edward P. (Chief Scientific Officer) | Option Ex | 4,204 | .00 | 0 |
| 2023-02-17 | Crockett Thomas Andrew (CEO) | Sale | 6,700 | 7.66 | 51,322 |
| 2023-02-17 | Crockett Thomas Andrew (CEO) | Option Ex | 12,749 | .00 | 0 |
| 2023-02-17 | Palleiko Benjamin L (President, CFO, CBO & Sec'y) | Sale | 4,954 | 7.66 | 37,947 |
| 2023-02-17 | Palleiko Benjamin L (President, CFO, CBO & Sec'y) | Option Ex | 9,363 | .00 | 0 |
| 2022-11-18 | Audhya Paul K. (Chief Medical Officer) | Sale | 722 | 5.44 | 3,927 |
| 2022-11-18 | Yea Christopher (Chief Development Officer) | Sale | 1,139 | 5.44 | 6,196 |
| 2022-11-18 | Feener Edward P. (Chief Scientific Officer) | Sale | 530 | 5.44 | 2,883 |
| 2022-11-18 | Crockett Thomas Andrew (CEO) | Sale | 1,785 | 5.44 | 9,710 |
| 2022-11-18 | Palleiko Benjamin L (CFO, CBO & Secretary) | Sale | 722 | 5.44 | 3,927 |
| 2022-11-17 | Audhya Paul K. (Chief Medical Officer) | Option Ex | 2,419 | .00 | 0 |
| 2022-11-17 | Yea Christopher (Chief Development Officer) | Option Ex | 1,774 | .00 | 0 |
| 2022-11-17 | Feener Edward P. (Chief Scientific Officer) | Option Ex | 1,774 | .00 | 0 |
| 2022-11-17 | Crockett Thomas Andrew (CEO) | Option Ex | 5,805 | .00 | 0 |
| 2022-11-17 | Palleiko Benjamin L (CFO, CBO & Secretary) | Option Ex | 2,419 | .00 | 0 |
| 2022-03-09 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 17.07 | 170,690 |
| 2022-01-07 | Feener Edward P. (Chief Scientific Officer) | Option Ex | 57,657 | 7.64 | 440,499 |
| 2021-11-01 | Yea Christopher (Chief Development Officer) | Sale | 5,000 | 18.07 | 90,330 |
| 2021-11-01 | Feener Edward P. (Chief Scientific Officer) | Sale | 6,000 | 18.07 | 108,426 |
| 2021-10-01 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 17.18 | 171,840 |
| 2021-08-02 | Yea Christopher (Chief Development Officer) | Sale | 5,000 | 20.52 | 102,579 |
| 2021-08-02 | Feener Edward P. (Chief Scientific Officer) | Sale | 6,000 | 20.52 | 123,131 |
| 2021-07-01 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 24.12 | 241,170 |
| 2021-06-17 | Crockett Thomas Andrew (CEO) | Sale | 1,067 | 30.04 | 32,050 |
| 2021-06-09 | Crockett Thomas Andrew (CEO) | Sale | 8,933 | 30.05 | 268,481 |
| 2021-06-02 | Feener Edward P. (Chief Scientific Officer) | Sale | 8,200 | 26.69 | 218,858 |
| 2021-06-01 | Smith Michael David (Senior VP, Development) | Sale | 7,500 | 26.83 | 201,225 |
| 2021-06-01 | Smith Michael David (Senior VP, Development) | Option Ex | 7,500 | 8.39 | 62,925 |
| 2021-06-01 | Feener Edward P. (Chief Scientific Officer) | Sale | 25,800 | 27.01 | 696,858 |
| 2021-05-03 | Yea Christopher (Chief Development Officer) | Sale | 5,000 | 24.84 | 124,195 |
| 2021-05-03 | Feener Edward P. (Chief Scientific Officer) | Sale | 6,000 | 24.84 | 149,052 |
| 2021-05-03 | Feener Edward P. (Chief Scientific Officer) | Option Ex | 6,000 | 10.21 | 61,260 |
| 2021-04-29 | Maetzel Andreas (Senior Vice President, Medical) | Sale | 40,886 | 25.04 | 1,023,581 |
| 2021-04-29 | Maetzel Andreas (Senior Vice President, Medical) | Option Ex | 40,886 | 10.73 | 438,829 |
| 2021-04-28 | Smith Michael David (Senior VP, Development) | Sale | 10,014 | 25.76 | 257,980 |
| 2021-04-28 | Smith Michael David (Senior VP, Development) | Option Ex | 10,014 | 8.39 | 84,017 |
| 2021-04-28 | Maetzel Andreas (Senior Vice President, Medical) | Sale | 36,127 | 25.48 | 920,696 |
| 2021-04-28 | Maetzel Andreas (Senior Vice President, Medical) | Option Ex | 36,127 | 7.91 | 285,764 |
| 2021-04-27 | Maetzel Andreas (Senior Vice President, Medical) | Sale | 11,017 | 25.79 | 284,161 |
| 2021-04-27 | Maetzel Andreas (Senior Vice President, Medical) | Option Ex | 11,017 | 7.91 | 87,144 |
| 2021-04-01 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 27.27 | 272,720 |
| 2021-02-23 | Yea Christopher (Chief Development Officer) | Sale | 15,000 | 33.48 | 502,275 |
| 2021-02-23 | Feener Edward P. (Chief Scientific Officer) | Sale | 31,000 | 33.41 | 1,035,555 |
| 2021-02-23 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 33.48 | 334,829 |
| 2021-02-23 | Palleiko Benjamin L (CFO, CBO & Secretary) | Sale | 29,642 | 33.49 | 992,769 |
| 2021-02-23 | Palleiko Benjamin L (CFO, CBO & Secretary) | Option Ex | 29,642 | 6.74 | 199,787 |
| 2021-01-04 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 18.49 | 184,920 |
| 2020-12-30 | Palleiko Benjamin L (CFO, CBO & Secretary) | Sale | 358 | 20.04 | 7,174 |
| 2020-12-30 | Palleiko Benjamin L (CFO, CBO & Secretary) | Option Ex | 358 | 6.74 | 2,412 |
| 2020-11-02 | Feener Edward P. (Chief Scientific Officer) | Sale | 6,000 | 17.14 | 102,810 |
| 2020-10-30 | Cha Albert (Director) | Buy | 115,686 | 17.25 | 1,995,814 |
| 2020-10-29 | Yea Christopher (Chief Development Officer) | Sale | 5,000 | 17.48 | 87,395 |
| 2020-10-21 | Yea Christopher (Chief Development Officer) | Sale | 6,044 | 18.35 | 110,919 |
| 2020-10-21 | Feener Edward P. (Chief Scientific Officer) | Sale | 9,007 | 18.20 | 163,936 |
| 2020-10-21 | Crockett Thomas Andrew (CEO) | Sale | 22,545 | 18.34 | 413,362 |
| 2020-10-20 | Yea Christopher (Chief Development Officer) | Sale | 7,942 | 17.64 | 140,120 |
| 2020-10-20 | Feener Edward P. (Chief Scientific Officer) | Sale | 7,900 | 17.63 | 139,308 |
| 2020-10-20 | Crockett Thomas Andrew (CEO) | Sale | 15,994 | 17.64 | 282,134 |
| 2020-10-16 | Yea Christopher (Chief Development Officer) | Sale | 914 | 17.00 | 15,538 |
| 2020-10-16 | Feener Edward P. (Chief Scientific Officer) | Sale | 993 | 17.00 | 16,881 |
| 2020-10-16 | Crockett Thomas Andrew (CEO) | Sale | 1,261 | 17.01 | 21,444 |
| 2020-02-05 | Yea Christopher (Chief Development Officer) | Sale | 100 | 17.10 | 1,710 |
| 2020-02-05 | Feener Edward P. (Chief Scientific Officer) | Sale | 100 | 17.11 | 1,711 |
| 2020-02-05 | Crockett Thomas Andrew (CEO) | Sale | 200 | 17.05 | 3,410 |
| 2019-12-20 | Yea Christopher (Chief Development Officer) | Sale | 2,646 | 17.02 | 45,024 |
| 2019-12-20 | Yea Christopher (Chief Development Officer) | Option Ex | 2,646 | .00 | 10 |
| 2019-12-20 | Crockett Thomas Andrew (CEO) | Sale | 2,300 | 17.02 | 39,150 |
| 2019-12-16 | Yea Christopher (Chief Development Officer) | Sale | 3,010 | 17.05 | 51,317 |
| 2019-12-16 | Yea Christopher (Chief Development Officer) | Option Ex | 3,010 | .00 | 12 |
| 2019-12-16 | Crockett Thomas Andrew (CEO) | Sale | 5,400 | 17.06 | 92,118 |
| 2019-12-13 | Yea Christopher (Chief Development Officer) | Sale | 1,500 | 17.05 | 25,567 |
| 2019-12-13 | Yea Christopher (Chief Development Officer) | Option Ex | 1,500 | .00 | 6 |
| 2019-12-13 | Crockett Thomas Andrew (CEO) | Sale | 2,200 | 17.06 | 37,536 |
| 2019-12-12 | Yea Christopher (Chief Development Officer) | Sale | 199 | 17.00 | 3,383 |
| 2019-12-12 | Yea Christopher (Chief Development Officer) | Option Ex | 199 | .00 | 0 |
| 2019-12-12 | Crockett Thomas Andrew (CEO) | Sale | 100 | 17.00 | 1,700 |
| 2019-09-27 | Soland Daniel B | Buy | 7,962 | 11.87 | 94,500 |
| 2019-09-26 | Soland Daniel B | Buy | 2,038 | 11.90 | 24,252 |
| 2019-07-29 | Cha Albert | Buy | 29,867 | 17.13 | 511,711 |
| 2019-07-26 | Cha Albert | Buy | 26,500 | 16.83 | 446,048 |
| 2019-07-23 | Feener Edward P. (Chief Scientific Officer) | Sale | 1,900 | 18.65 | 35,438 |
| 2019-07-22 | Yea Christopher (Chief Development Officer) | Sale | 7,355 | 18.34 | 134,927 |
| 2019-07-22 | Yea Christopher (Chief Development Officer) | Option Ex | 7,355 | .00 | 29 |
| 2019-07-22 | Feener Edward P. (Chief Scientific Officer) | Sale | 1,400 | 18.57 | 26,003 |
| 2019-07-19 | Cha Albert | Buy | 60,000 | 17.76 | 1,065,480 |
| 2019-07-17 | Cha Albert | Buy | 1,280 | 16.95 | 21,696 |
| 2019-07-15 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 17.04 | 170,410 |
| 2019-04-22 | Yea Christopher (Chief Development Officer) | Sale | 7,355 | 26.36 | 193,841 |
| 2019-04-22 | Yea Christopher (Chief Development Officer) | Option Ex | 7,355 | .00 | 29 |
| 2019-04-22 | Palleiko Benjamin L (CBO, CFO and Secretary) | Sale | 2,000 | 25.80 | 51,604 |
| 2019-04-22 | Palleiko Benjamin L (CBO, CFO and Secretary) | Option Ex | 2,000 | 8.39 | 16,780 |
| 2019-04-18 | Palleiko Benjamin L (CBO, CFO and Secretary) | Sale | 1,073 | 25.51 | 27,373 |
| 2019-04-18 | Palleiko Benjamin L (CBO, CFO and Secretary) | Option Ex | 1,073 | 6.74 | 7,232 |
| 2019-04-17 | Feener Edward P. (Chief Scientific Officer) | Sale | 4,000 | 25.08 | 100,336 |
| 2019-04-15 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 25.34 | 253,420 |
| 2019-04-10 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 13,531 | 29.39 | 397,743 |
| 2019-04-09 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 13,669 | 28.53 | 389,990 |
| 2019-04-08 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 22,800 | 29.49 | 672,417 |
| 2019-04-05 | Maetzel Andreas (Senior Vice President Medical) | Sale | 5,000 | 30.00 | 150,010 |
| 2019-04-05 | Maetzel Andreas (Senior Vice President Medical) | Option Ex | 5,000 | 7.91 | 39,550 |
| 2019-04-02 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 9,141 | 28.76 | 262,931 |
| 2019-04-01 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 52,831 | 27.66 | 1,461,199 |
| 2019-03-29 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 35,102 | 28.40 | 996,756 |
| 2019-03-28 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 36,665 | 27.80 | 1,019,323 |
| 2019-03-27 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 57,917 | 29.06 | 1,683,010 |
| 2019-03-26 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 30,093 | 29.70 | 893,701 |
| 2019-03-18 | Shah Nimish P (10% Owner) | Sale | 500,000 | 28.75 | 14,375,000 |
| 2019-03-18 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 262,470 | 26.70 | 7,007,949 |
| 2019-03-14 | Crockett Thomas Andrew (CEO) | Sale | 3,000 | 30.16 | 90,483 |
| 2019-03-05 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 32,332 | 23.04 | 744,832 |
| 2019-03-04 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 43,378 | 22.91 | 993,659 |
| 2019-02-21 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 172,543 | 20.60 | 3,554,385 |
| 2019-02-20 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 23,235 | 20.02 | 465,071 |
| 2019-02-19 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 18,420 | 20.73 | 381,901 |
| 2019-01-25 | Yea Christopher (Chief Development Officer) | Sale | 5,453 | 17.06 | 93,017 |
| 2019-01-25 | Yea Christopher (Chief Development Officer) | Option Ex | 5,453 | .00 | 21 |
| 2019-01-23 | Yea Christopher (Chief Development Officer) | Sale | 600 | 17.01 | 10,204 |
| 2019-01-23 | Yea Christopher (Chief Development Officer) | Option Ex | 600 | .00 | 2 |
| 2019-01-22 | Yea Christopher (Chief Development Officer) | Sale | 1,302 | 17.00 | 22,139 |
| 2019-01-22 | Yea Christopher (Chief Development Officer) | Option Ex | 1,302 | .00 | 5 |
| 2019-01-16 | Feener Edward P. (Chief Scientific Officer) | Sale | 4,000 | 19.51 | 78,024 |
| 2019-01-14 | Crockett Thomas Andrew (CEO) | Sale | 10,000 | 19.57 | 195,710 |
| 2019-01-07 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 2,599 | 20.41 | 53,050 |
| 2019-01-03 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 1,700 | 20.01 | 34,022 |
| 2019-01-02 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 200 | 20.00 | 4,000 |
| 2018-12-31 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 25,418 | 20.00 | 508,461 |
| 2018-12-28 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 3,734 | 20.03 | 74,780 |
| 2018-12-19 | Sv Life Sciences Fund Iv, L.p. (10% Owner) | Sale | 2,136 | 20.02 | 42,758 |
| 2018-09-10 | Cha Albert | Buy | 1,058,824 | 17.00 | 18,000,008 |
| 2018-09-10 | Oronsky Arnold L | Buy | 58,824 | 17.00 | 1,000,008 |
| 2017-10-12 | Shah Rajeev M. | Buy | 850,000 | 8.50 | 7,225,000 |
| 2017-10-12 | Novo Holdings A/s (10% Owner) | Sale | 1,726,481 | 9.26 | 15,987,214 |
| 2017-10-12 | Kolchinsky Peter | Buy | 850,000 | 8.50 | 7,225,000 |
| 2017-10-12 | Aldrich Richard (Director) | Buy | 565,065 | 8.61 | 4,866,904 |
| 2017-10-11 | Novo Holdings A/s (10% Owner) | Sale | 35,519 | 10.21 | 362,755 |
| 2017-10-10 | Novo Holdings A/s (10% Owner) | Sale | 963,283 | 12.78 | 12,309,793 |
| 2017-09-15 | Novo Holdings A/s (10% Owner) | Sale | 140,747 | 7.50 | 1,055,883 |
| 2017-09-14 | Novo Holdings A/s (10% Owner) | Sale | 10,000 | 8.05 | 80,500 |
| 2017-09-13 | Novo Holdings A/s (10% Owner) | Sale | 25,900 | 8.02 | 207,614 |
| 2016-11-21 | Maroney Marcee (VP, Clinical Affairs) | Option Ex | 4,664 | 7.84 | 36,565 |
| 2016-11-21 | Renzi David (President & CEO) | Option Ex | 36,640 | 7.84 | 287,257 |
| 2016-11-21 | Basta Steven L | Option Ex | 1,125 | 7.84 | 8,820 |
| 2015-12-30 | Renzi David (President & CEO) | Sale | 10,000 | 3.70 | 37,000 |
| 2015-12-30 | Renzi David (President & CEO) | Option Ex | 10,000 | .56 | 5,600 |
| 2015-04-14 | Vivo Ventures Vi Affiilates Fund, L.p. (10% Owner) | Buy | 1,012,500 | 5.00 | 5,062,500 |
| 2015-04-14 | Cha Albert (Director) | Buy | 1,012,500 | 5.00 | 5,062,500 |
| 2015-04-14 | Nasr Khaled (10% Owner) | Buy | 810,000 | 5.00 | 4,050,000 |
| 2015-04-14 | Nohra Guy P (Director) | Buy | 877,500 | 5.00 | 4,387,500 |
| 2015-04-14 | Janney Daniel (10% Owner) | Buy | 877,500 | 5.00 | 4,387,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of KALV listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kalvista Pharmaceuticals, Inc. (symbol KALV, CIK number 1348911) see the Securities and Exchange Commission (SEC) website.